Hormonal and nonhormonal desensitization in isolated bone cells

Response to continuous and pulsatile PTH dosing: a mathematical model for parathyroid hormone receptor kinetics

In this paper, we propose a mathematical model for parathyroid hormone receptor (PTH1R) kinetics, focusing on the receptor's response to PTH dosing to discern bone formation responses from bone resorption. The PTH1R is a major target for new osteoporosis treatments, as pulsatile PTH dosing has been shown to induce net bone formation in both animals and humans, and PTH(1-34) was recently FDA approved for the treatment of post-menopausal osteoporosis. PTH has also been shown to cause net bone loss when given continuously, so that the net action of PTH on bone is dependent on the dosing pattern. We have developed a simplified two-state receptor kinetics model for the PTH1R, based on the concepts of Segel et al., to distinguish the activity of active and inactive receptor and receptor-ligand complexes. The goal is to develop a plausible model of the minimal essential biological relationships necessary for understanding the responses to PTH dosing. A two-state model is able to effectively discriminate between continuous and pulsatile PTH dosing using the active species as surrogates for the downstream anabolic response. For continuous PTH dosing, the model predicts a desensitized system dominated by the inactive receptor and complex, consistent with downstream net bone loss that has been demonstrated experimentally. Using pulsatile PTH dosing, the model system predicts a highly sensitized state dominated by the active receptor and complex, corresponding to net bone formation. These results are consistent with the hypothesis that the kinetics of the receptor plays a critical role in the downstream effects of PTH dosing. Moreover, these results indicate that within a range of biologically relevant PTH doses, the two-state model is able to capture the differential behavior of the system for both continuous and pulsatile PTH dosing. The development of such a model provides a rational basis for developing more biologically extensive models that may support the design of optimal dosing strategies for PTH-based anti-osteoporosis treatments. Moreover, this model provides a unique starting point from which to design experiments investigating PTH receptor biology.

Coordinate regulation of PTH/PTHrP receptors by PTH and calcitriol in UMR 106-01 osteoblast-like cells

High levels of PTH result in desensitization of target cells to further stimulation with PTH in vivo and in vitro. While studies in vitro demonstrate that the effect of PTH can be direct, it is also possible that studies in vivo may be complicated by the fact that other potential regulators of PTH action, such as increased levels of calcitriol, may play a role. Thus, we examined the actions of calcitriol and PTH on PTH/PTHrP-receptor expression in confluent cultures of UMR 106-01 osteoblast-like cells treated with calcitriol, PTH or both hormones for one to three days. Following these treatments, studies of PTH receptor binding, cAMP generation, and steady-state levels of PTH/PTHrP receptor mRNA were performed. Exposure to PTH resulted in a decrease in PTH stimulated cAMP generation by 88 +/- 2%, and PTH binding by 63 +/- 3%. Levels of PTH/PTHrP-receptor mRNA decreased progressively reaching 20% of control values after three days of PTH (100 nM) treatment. Calcitriol also resulted in a dose and time-dependent decrease in PTH/PTHrP-receptor mRNA, decreasing by 72 +/- 4% after 48 hours. PTH receptor binding and cAMP generation were diminished by 42 +/- 3% and 42 +/- 4%, respectively. Co-incubation of UMR 106-01 cells with submaximal doses of calcitriol and PTH together revealed that the levels of PTH/PTHrP-receptor mRNA were decreased by both hormones together to a greater extent than with either alone. These studies show that both calciotropic hormones, PTH and calcitriol, are potent regulators of PTH/PTHrP-receptor gene expression in UMR 106-01 osteoblast-like cells. Thus, stimulation of calcitriol production by PTH may result in a coordinated down-regulation of PTH receptor expression by these hormones.

H(+)-stimulated release of prostaglandin E2 and cyclic adenosine 3',5'-monophosphoric acid and their relationship to bone resorption in neonatal mouse calvaria cultures

The addition of protons to the medium of neonatal mouse calvaria cultures stimulated bone resorption and release of calcium into the medium. In addition, added protons significantly increased the release of prostaglandin E2 (PGE2) and cyclic adenosine 3',5'-monophosphoric acid (cAMP) from the bones. Indomethacin significantly inhibited the release of calcium, PGE2 and cAMP from proton-treated cultures. The positive control, parathyroid hormone (PTH)-treated cultures, also gave rise to bone resorption and calcium release into the medium. However, unlike the addition of protons, the addition of PTH did not stimulate PGE2 release nor did indomethacin inhibit calcium release from PTH-treated cultures. In addition, indomethacin only slightly inhibited cAMP release from PTH-treated cultures, as compared to the marked inhibition by indomethacin of cAMP release from proton-treated cultures. These findings indicate that bone resorption due to added protons is dependent on both PGE2 and cAMP production, whereas bone resorption due to PTH only involves cAMP production.

Interleukin 1 interacts synergistically with forskolin and isobutylmethylxanthine in stimulating bone resorption in organ culture

This study examined the interaction of interleukin 1 (IL-1) with forskolin and isobutyl-methylxanthine (3-isobutyl-1-methyl-xanthine) (IBMX) in stimulating bone resorption in 5-day fetal rat long bone organ culture. Forskolin and IBMX are pharmacologic agents that elevate cyclic adenosine monophosphate (AMP) levels in many cell types, including osteoblasts and osteoclasts. The interaction of IL-1 with forskolin and IBMX are synergistic when submaximal resorptive concentrations of agonists were examined. Stimulated resorption was 2 to 5 times that expected for an additive response. When maximally resorptive concentrations of agonists were examined, the interaction between IL-1 and the other agents was, at most, additive. We have previously reported that parathyroid hormone and prostaglandin E, agents that also activate the cyclic AMP pathway in bone cells, interact synergistically with IL-1 in stimulating bone resorption. The results of this study, together with our previous studies, suggest that activation of the cyclic AMP pathway is a sufficient signal for an agent to interact synergistically with IL-1 in stimulating bone resorption.

Effect of parathyroid hormone on phospholipid metabolism in osteoblast-like rat osteogenic sarcoma cells

Previous results have shown that 1,25-dihydroxycholecalciferol [1,25(OH)2D3] enhances the synthesis of phosphatidylserine (PS) and suppresses the synthesis of phosphatidylethanolamine (PE) in osteoblast-like rat osteogenic sarcoma UMR 106 cells [Matsumoto, Kawanobe, Morita & Ogata (1985) J. Biol. Chem. 260, 13704-13709]. In the present study, the effect of parathyroid hormone (PTH) on phospholipid metabolism is examined by using these cells. Treatment of UMR 106 cells with human PTH-(1-34)-peptide suppresses the synthesis of phosphatidylethanolamine in a dose- and time-dependent manner without affecting the synthesis of PS. The maximal effect on PE synthesis is obtained with 2.4 nM-human PTH-(1-34)-peptide when the cells are treated for 48 h or longer. In addition, when human PTH-(1-34)-peptide is added together with the maximal dose of 1,25(OH)2D3, there is a further decline in PE synthesis, whereas the stimulation of PS synthesis by 1,25(OH)2D3 is not altered. Because methylation of PE is suggested to affect hormone receptor-adenylate cyclase coupling, the observed change in PE metabolism by PTH and 1,25(OH)2D3 may be, at least in part, involved in the development of desensitization phenomenon to PTH in these cells.

Prostaglandin E2 and 2-chloroadenosine act in concert to stimulate bone resorption in cultured murine calvarial bones

2-Chloroadenosine-induced calcium release from cultured mouse calvarial bones is reduced by inhibitors of prostaglandin production, whereas PTH stimulated calcium release is not. When calvaria were treated with 2-chloroadenosine (10 microM) for 48 hr the production of PGE was significantly increased. The stimulation of PGE synthesis was totally inhibited by indomethacin (1 microM) and partially by hydrocortisone (0.1 microM). When PGE2 and 2-chloroadenosine, at submaximal concentrations, were simultaneously added to cultures of calvarial bones, in which the endogenous production of prostaglandins was reduced by indomethacin, a supraaditive effect on calcium mobilization by the two agents was seen. No such synergism could be observed between PGE2 and PTH or between 2-chloroadenosine and PTH. The degree of stimulation in indomethacin-treated bones by 2-chloroadenosine (i.e. when compared to indomethacin-treated controls) was almost the same as that seen in bones stimulated by 2-chloroadenosine in the absence of indomethacin. These data suggest that 2-chloroadenosine can induce bone resorption by a mechanism independent of stimulation of prostaglandin synthesis but that the amount of 2-chloroadenosine stimulated resorption is enhanced by endogenous and exogenous PGE2.

Adriamycin inhibits PTH-mediated but not PGE2-mediated stimulation of cyclic AMP formation in isolated bone cells

We have examined the effect of adriamycin, an anthracycline antibiotic which modifies plasma membrane functions, on the cyclic AMP response to PTH and PGE2 in isolated osteoblastlike cells. Adriamycin blunted the increment in bone cell cyclic AMP caused by exposure to PTH. This effect appeared rapidly (within 3 min after bone cells were exposed to adriamycin) and disappeared soon after exposure of adriamycin-treated cells to adriamycin-free incubation medium. Inhibition was evident over the entire time course of PTH action, at low as well as high PTH concentrations, and was one-half maximal at 31 microM adriamycin. It could not be attributed to alterations in cyclic AMP exodus, degradation or interference with the cyclic AMP assay, nor to impaired cell viability. Adriamycin also reduced the stimulatory effect of PTH on adenylate cyclase activity in a crude plasma membrane preparation. By contrast, adriamycin failed to modify the effects of PGE2 on cyclic AMP generation in intact bone cells, and on adenylate cyclase activity in broken cells. Moreover, concentrations of adriamycin that blunted the effect of PTH on adenylate cyclase activity did not inhibit the stimulatory effects of sodium fluoride or of GppNHp. These results suggest that adriamycin selectively alters the interaction between PTH and its receptor or impairs the transmission of information from hormone-receptor complex to adenylate cyclase (or both), perhaps by binding to specific lipid domains in the plasma membrane. Structural analogues of adriamycin, which vary in their lipophilic properties, also varied in their capacity to perturb the cyclic AMP response.(ABSTRACT TRUNCATED AT 250 WORDS)

Effects of vitamin D and parathyroid hormone on cyclic AMP production by bone cells isolated from rat calvariae

Studies presented here were designed to investigate further the basis for an impaired cAMP response to parathyroid hormone (PTH) in osteoblastlike calvarial bone cells isolated from vitamin D-deficient rat pups. The goal was to perturb Ca, PTH, and vitamin D in vivo in order to see which factors might be responsible for the impaired in vitro bone cell cAMP response. Pups either were parathyroidectomized (PTX) 3-5 days, implanted with osmotic minipumps delivering high doses of PTH, given repeated, high doses of 1,25(OH)2D3, or were D-deficient (-D, i.e., born and suckled by D-deficient mothers). Osteoblastlike bone cells, isolated by sequential enzyme digestion and centrifugation, were exposed to PTH for 5 min in the presence of a phosphodiesterase inhibitor. In bone cells isolated from -D rat pups, both basal and PTH-induced cAMP accumulation were significantly lower than in +D bone cells. Earlier, we had shown that two daily injections of -D pups with 50 ng 1,25(OH)2D3 restores this reduced bone cAMP response of -D pups toward normal. In the present study, neither basal nor PTH-induced bone cell cAMP accumulation was affected by subjecting D-replete pups to PTX, PTH infusion, or repeated high doses of 1,25(OH)2D3 despite the fact that each treatment markedly changed serum Ca or serum immunoreactive PTH. The results indicate that the impaired bone cell cAMP response seen in -D pups is not a direct result of chronic hypocalcemia and that the "heterologous desensitization" seen in vitro with added 1,25(OH)2D3 could not be duplicated by in vivo treatment of +D pups with supraphysiologic doses of 1,25(OH)2D3.(ABSTRACT TRUNCATED AT 250 WORDS)

Rheumatoid synovial cell hormone responses modulated by cell-cell interactions

Cellular interactions within the rheumatoid synovium are likely to be responsible for the destructive properties of this tissue. The responses to hormones which regulate connective tissue metabolism may also be influenced by these cell-cell interactions. To determine the effect of cellular interactions on responses to hormones, human peripheral blood mononuclear cells were cocultured with adherent rheumatoid synovial cells. Coculture resulted in a decrease in response to prostaglandin E2 as assessed by a reduction in the magnitude of the acute prostaglandin-induced cyclic AMP response. In contrast, coculture resulted in an increase in the magnitude of the acute parathyroid hormone-induced cyclic AMP response. The decrease in response to prostaglandin was reversed by the presence of indomethacin during the preincubation, whereas indomethacin had no effect on the cyclic AMP response to parathyroid hormone. Increases in endogenous synovial cell prostaglandin production (stimulated by soluble factors released by the mononuclear cells) accounted for the subsequent decrease in the response to exogenous prostaglandin. The increase in cyclic AMP response to parathyroid hormone could not be explained by a soluble factor and was independent of ambient prostaglandin levels.

Osteoporosis: a bone turnover defect resulting from an elevated parathyroid hormone concentration within the bone-marrow cavity?

Recently the bone-marrow cavity blood concentration of parathyroid hormone (PTH) has been shown to exceed that of the peripheral blood. As PTH is a primary modulator of bone cell activity, altered levels of the hormone in the bone-marrow blood may play a significant role in the aetiology of bone disease. We therefore measured PTH concentrations in marrow cavity and venous blood of 9 osteoporotic and 14 control subjects using sequence specific radioimmunoassays for intact and mid-carboxyl (Mid-C) regional human PTH (hPTH). Intact and Mid-C PTH levels were identical in the peripheral blood of control and osteoporotic subjects. Furthermore, bone-marrow cavity blood concentrations of Mid-C PTH, whilst universally higher than those found in peripheral blood, were also comparable in the osteoporotic and control subjects. The sole difference in the PTH composition of bone-marrow cavity blood from osteoporotic subjects was an increased concentration of intact PTH. The origins and consequences of elevated levels of intact PTH within the marrow cavity blood of osteoporotic subjects are discussed.

The metabolism of lead in isolated bone cell populations: interactions between lead and calcium

Previous studies of lead metabolism in bone organ culture have defined, in part, an exchangeable bone lead compartment regulated by the same ions and hormones that normally control bone cell metabolism. This study was undertaken to further characterize this subcompartment of exchangeable lead and to examine possible interactions between lead and calcium in isolated bone cell populations. Bone cells, derived from mouse calvaria, were enriched for osteoclasts (OC) and osteoblasts (OB) by a sequential collagenase digestion. We found that (1) the uptake of 210Pb by OC cells was rapid, and OC cells had greater avidity for lead, compared to OB cells, at concurrent time points of incubation, (2) OB cells showed very little increase in lead uptake as medium lead concentrations were increased from 6.5 to 65 microM, in contrast, the uptake of lead by OC cells was almost linear, (3) after loading OC cells with 210Pb, significant release of label (approximately 15 to 30%) occurred within short time periods (less than or equal to 2 hr) during incubations in chase medium, (4) parathyroid hormone (PTH) at physiological concentrations effected a marked increase in 210Pb and 45Ca uptake in OC cells, after 5 min of incubation, Pb accumulation into OC cells continued as calcium uptake markedly decreased, (5) this PTH effect on 210Pb uptake was linear over PTH concentrations of 50 to 250 ng/ml, and (6) rising medium concentrations of lead (greater than or equal to 26 microM) markedly enhanced/exaggerated calcium uptake by OC cells, far above that produced by physiological concentrations of PTH. These data indicate that (1) quantitatively, OC cells are the predominant cell type in the metabolism of lead in this in vitro system of OC and OB cell monolayers, (2) mediated incorporation of lead into OC cells occurs and likely involves changes in membrane permeability effected by hormonal stimuli, such as PTH, and (3) modulations in cellular calcium metabolism induced by lead at low concentration may have the potential of disturbing multiple cell functions of different tissues that depend upon calcium as a second messenger.

Comparison of inhibition of bone resorption and escape with calcitonin and dibutyryl 3',5' cyclic adenosine monophosphate

Both parathyroid hormone (PTH) and calcitonin (CT) can increase the concentration of cyclic 3',5' adenosine monophosphate (cAMP) in fetal rat bone in organ culture. Moreover, dibutyryl cAMP (dbcAMP) can both stimulate and inhibit 45Ca release from such bones depending on dose and experimental conditions. In this study we compared dbcAMP and CT for their effects on bones pretreated with PTH. Both compounds produced transient inhibition of bone resorption followed by escape. Escape from dbcAMP was independent of prostaglandin synthesis, since it occurred both in the presence and absence of indomethacin, a prostaglandin cyclo-oxygenase inhibitor.